Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT Study of Suzetrigine (VX-548)
NCT05818852Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of suzetrigine in acute pain (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Change in QT interval corrected by Fridericia's formula at Day 12. Started Apr 2023; status: completed.
02
Drugs
suzetrigine
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT05818852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05818852.